RxDoctor Payments Data

Kristy Beams

Psychiatric/Mental Health · Jacksonville, FLNPI 1952829731

Payments from drug & device makers

$1,004in general payments, 2019–2025

Across 60 payments — averaging $16.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$455
  • Otsuka America Pharmaceutical, Inc.$202
  • Neurocrine Biosciences, Inc.$56
  • Vanda Pharmaceuticals Inc.$53
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$51
  • Neos Therapeutics, LP$43
  • plus $144 from 8 others

What the payments were for

  • Food & beverage$1,004100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,004 in reported general payments places this provider in the 55th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$23,657
Medicare patients
62
Services billed
227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine23$128,470
VraylarCariprazine Hcl27$37,100
Lurasidone Hcl13$5,170
Aripiprazole42$2,799
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine51$1,781
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl19$1,461
Alprazolam85$1,105
Buspirone Hcl72$934
Buprenorphine Hcl18$897
Oxcarbazepine24$549
Trazodone Hcl114$527
Escitalopram Oxalate26$521
Clonazepam91$450
Quetiapine Fumarate46$442
Bupropion XlBupropion Hcl35$438

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$14$128,47023 claims
AbbVieVraylar$455$37,10027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →